First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.

Abstract

3029Background: MK-1248 is a humanized IgG4 agonist monoclonal antibody (mAb) that targets GITR. GITR is expressed on regulatory T cells (Treg), resting CD4+ and CD8+ T cells, NK (natural killer) c...